HP537

Search documents
海创药业暂停HP501研发 8000万元投入付诸东流
Zhong Guo Jing Ying Bao· 2025-08-23 13:18
中经记者苏浩卢志坤北京报道 2018年11月,海创药业自主研发的高尿酸血症和痛风1类新药HP501缓释片获得国家药监局颁发的《临 床试验通知书》。公司满怀希望地宣布,这款具有自主知识产权的URAT1抑制剂将为中国1.3亿高尿酸 血症患者带来新希望。 然而,近七年后,2025年8月13日,海创药业在发布年中财报的同时宣布了一则消息:拟暂停HP501项 目的研发推进。此时,该项目已投入募集资金8111.25万元。 决定背后的原因是残酷的市场竞争:国内已有药企针对URAT1靶点的产品获批上市,并有多项围绕该 靶点的Ⅲ期临床研究正在进行。 8月22日,海创药业方面在接受《中国经营报》记者采访时表示,募投项目子项目调整是基于公司实际 情况并结合当前市场竞争格局、行业发展趋势等多重因素决定的。上述调整将更好地维护公司和广大投 资者的利益,符合公司的长远发展及规划。不会对公司当期经营业绩产生重大影响,不存在损害股东利 益的情形。 从临床到落寞 据了解,HP501是海创药业自主研发的小分子化学创新药,为尿酸盐阴离子转运体1(URAT1)抑制 剂。临床前研究结果显示,其生物活性优于同类药物,展现了优良的药代动力学和毒理学性质。 ...
海创药业股份有限公司2025年半年度报告摘要
Shang Hai Zheng Quan Bao· 2025-08-13 18:28
Group 1 - The company has approved a special report on the storage and actual use of raised funds for the first half of 2025, ensuring compliance with relevant regulations [7][17][46] - The total amount raised from the public offering was RMB 1,062,699,200, with a net amount of RMB 995,113,315 after deducting issuance costs [7][25] - As of June 30, 2025, the company has used RMB 871,447,067.89 of the raised funds, with a remaining balance of RMB 147,244,678.39 [8][9] Group 2 - The company has adjusted the investment projects related to the raised funds, specifically suspending further development of the HP501 project due to market competition [27][31] - The remaining funds from the "Innovative Drug R&D Project" will be redirected to ongoing projects HP518 and HP537 [27][30] - The adjustments are aimed at improving the efficiency of fund usage and aligning with the company's long-term strategic goals [31][33] Group 3 - The company has decided to cancel its supervisory board, with its functions being transferred to the audit committee of the board of directors [48][69] - Amendments to the company's articles of association have been proposed to align with the new Company Law and improve governance [49][80] - The company has also revised several internal governance documents to enhance management efficiency and compliance with updated regulations [81]